What is Cycloastragenol?
The most researched natural telomerase activator — a triterpenoid saponin from Astragalus membranaceus with documented effects on cellular aging, immune function, and telomere maintenance.
Molecule Identity
A Natural Molecule with a Synthetic Problem
Cycloastragenol (CAG) is a triterpenoid saponin aglycone — the bioactive core molecule left after removing sugar chains from astragaloside IV, the primary saponin in Astragalus membranaceus. Unlike its precursor, CAG is small enough to cross cell membranes and directly interact with telomerase regulatory pathways.
First isolated and characterized in the 1990s, CAG gained scientific attention after Harley et al. (2011) demonstrated its ability to activate telomerase in human immune cells. Since then, it has become the most studied natural compound for telomere maintenance — though its extreme hydrophobicity and rapid hepatic metabolism have made effective oral delivery a persistent challenge.
How CAG Works: The Telomerase Pathway
Telomeres are protective caps at the ends of chromosomes that shorten with each cell division. When they become critically short, cells enter senescence — a state of irreversible growth arrest that drives tissue aging. Telomerase is the enzyme that rebuilds these caps, but it is silenced in most adult somatic cells.
CAG appears to reactivate telomerase expression through the ERK/MAPK signaling pathway, increasing hTERT (the catalytic subunit of telomerase) mRNA and protein levels. Molgora et al. (2013) demonstrated this in human CD4+ and CD8+ T cells, showing enhanced proliferative capacity and reduced expression of senescence markers.
Telomere Lengthening
Reactivates telomerase to rebuild chromosome end-caps, delaying cellular senescence in immune and progenitor cells.
Immune Rejuvenation
Restores proliferative capacity in CD8+ T cells and NK cells — critical for immune surveillance in aging.
Cellular Protection
Reduces oxidative stress markers and DNA damage accumulation in aging cell populations.
Metabolic Support
Improves mitochondrial function and ATP production in senescent cell models.
From Traditional Medicine to Modern Science
Astragalus has been used in Traditional Chinese Medicine for over 2,000 years. The isolation of cycloastragenol and the discovery of its telomerase-activating properties represent a bridge between ethnobotanical knowledge and molecular geroscience.
The Bioavailability Crisis: Why Most CAG Never Reaches Your Cells
This is the central problem that defines the cycloastragenol market — and the reason TELOGENIS exists. Standard oral CAG is extraordinarily difficult to deliver effectively.
Three Barriers to Absorption
Extreme Hydrophobicity
CAG is virtually insoluble in water. In the aqueous environment of the GI tract, it precipitates out of solution before absorption can occur.
Hepatic First-Pass
CAG is rapidly metabolized by CYP3A4 and CYP2D6 in the liver. Zhu et al. (2010) documented 91.8% removal in just 30 minutes in human liver microsomes.
P-gp Efflux
The P-glycoprotein efflux pump actively transports absorbed CAG back out of intestinal enterocytes, further reducing net absorption.
The math is brutal: A standard 10 mg CAG capsule may deliver less than 1 mg to systemic circulation. The rest is metabolized, excreted, or never dissolved in the first place. This is why delivery technology matters more than milligram counts.
How TELOGENIS Solves the Delivery Problem
The TELOGENIS Delivery Matrix is a four-stage, multi-vector absorption architecture designed specifically to overcome each barrier to CAG bioavailability. It is not a single ingredient — it is an engineered system.
| Stage | Technology | Barrier Addressed | Documented Effect |
|---|---|---|---|
| 1. Solubility | HPβCD molecular encapsulation + Syloid® | Water insolubility | 2–4× AUC increase |
| 2. Transport | Liposomal phospholipids + LCT/MCT oils | Hepatic first-pass | 3–5× bioavailability; lymphatic bypass |
| 3. Activation | Piperine, Naringin, Gingerol, Bergamottin, Sodium Caprate | CYP3A4 metabolism; P-gp efflux | 2–20× bioenhancement |
| 4. Absorption | Lymphatic lacteals → thoracic duct | Portal vein delivery | Bypasses liver entirely |
Cycloastragenol vs. NMN: Complementary, Not Competitive
Two of the most discussed longevity compounds target entirely different aging mechanisms. Understanding the distinction is essential for informed supplementation.
| Feature | Cycloastragenol (CAG) | NMN |
|---|---|---|
| Primary Target | Telomerase enzyme (hTERT upregulation) | NAD+ synthesis (NAMPT pathway) |
| Cellular Action | Maintains telomere length | Restores NAD+ for energy metabolism |
| Human RCT Data | Yes (Harley 2011, Salvador 2016, de Jaeger 2024) | Limited (mostly preclinical/animal) |
| Bioavailability Challenge | 91.8% hepatic first-pass loss | Degraded by CD38 in bloodstream |
| Typical Dose | 5–50 mg daily | 250–1000 mg daily |
| Cost (30-day) | $55–$80 | $40–$120 |
Verdict: CAG and NMN are complementary. CAG maintains the "biological clock" (telomeres). NMN restores the "cellular battery" (mitochondria via NAD+). Sophisticated longevity protocols use both. Read the full comparison →
Dosing, Safety & What to Expect
Evidence-Based Dosing Range
Human studies have used doses ranging from 5 mg to 50 mg daily, typically divided into one or two doses. The Salvador 2016 RCT found a complex dose-response: low-dose TA-65 lengthened telomeres, but high dose did not, suggesting an optimal therapeutic window rather than a linear "more is better" relationship.
Entry Level: 5–10 mg
Maintenance and prevention. Suitable for younger adults or those starting a longevity protocol. CAG CORE provides 10 mg per capsule.
Standard: 20 mg
Therapeutic protocol aligned with published human data. CAG PLUS provides 20 mg per serving (2 capsules).
Advanced: 17 mg (Enhanced)
Maximum absorption efficiency with piperine + naringin bioactivation. CAG MAX delivers 17 mg with the full activation complex.
Safety Profile
CAG has a favorable safety profile in published human studies. No serious adverse events were reported in the Salvador 2016 (n=117, 12 months) or de Jaeger 2024 (n=40, 6 months) trials. Mild GI discomfort has been reported in a small percentage of users.
Important considerations:
- CAG may interact with CYP3A4-metabolized medications (the same pathway it inhibits)
- Not recommended for individuals with active cancer (theoretical concern about telomerase reactivation)
- Not studied in pregnancy or breastfeeding — avoid
- Quality varies enormously between brands; verify third-party testing
Frequently Asked Questions
No. Astragalus extract contains hundreds of compounds. Cycloastragenol is a single, isolated molecule — the aglycone of astragaloside IV. Most astragalus supplements contain negligible amounts of CAG. TA-65 is a proprietary extract standardized for CAG content, but its exact composition is not publicly disclosed.
Telomere length changes were detected at 6 months in the de Jaeger 2024 RCT and 12 months in Salvador 2016. Immune markers may shift earlier. CAG is not a "feel it today" compound — it works at the cellular level over months to years.
Yes. They target different mechanisms (telomeres vs. NAD+/mitochondria) and have no known negative interactions. Many longevity researchers consider them complementary. The optimal stack for healthspan optimization is CAG 17 mg + NMN 500 mg daily.
Milligram count is not the same as delivered dose. CAG MAX includes piperine and naringin, which are documented to increase bioavailability 2–20×. The 17 mg in MAX may deliver more active CAG to circulation than 20 mg of a standard formulation. It's "MAX" for absorption efficiency, not raw milligrams.
This is the most important theoretical concern. Telomerase is active in ~90% of cancers, so reactivating it in somatic cells raises a logical red flag. However, Bernardes de Jesus et al. (2012) demonstrated that telomerase gene therapy in mice delayed aging without increasing cancer incidence. The dose, duration, and tissue specificity matter enormously. CAG is not recommended for individuals with active malignancies.
Ready to Experience the Difference?
Don't settle for standard CAG that loses 91.8% to hepatic metabolism. The TELOGENIS Delivery Matrix is engineered for absorption.